



## SEPTEMBER SEMINAR NOTICE

*Presented by*

**Yale School of Medicine's, Department of Therapeutic Radiology**

# **“Inducing Tumor ‘BRCA-ness’ with Targeted Therapies”**

**Alanna Kaplan, MD/PhD Student  
Yale School of Medicine**

**Date: Thursday, September 10, 2020, 9:00AM**

**Location: Zoom Meeting**

**Course Director/Host: Henry S. Park, MD, MPH**

*There is no corporate support for this activity*

This course will fulfill the licensure requirement set forth by the State of Connecticut

### **ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **TARGET AUDIENCE**

Attending Physicians; Housestaff/Fellows; Medical Students; Nurses; PA's; Other

### **NEEDS ASSESSMENT**

The use of PARP inhibitors has shown efficacy in the treatment of cancers with DNA repair defects secondary to BRCA mutations. Growing evidence suggests that combining PARP inhibitors with other therapeutic agents may allow for the expansion of their use to cancers without BRCA mutations. An increased understanding of the mechanisms underlying the efficacy of these combination therapies will help guide the development of improved treatment regimens.

### **LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. To review the role of PARP inhibitor therapy in BRCA-mutant and HR-deficient cancers
2. To understand the results of recent clinical trials combining anti-angiogenics and PARP inhibitors

3. To appreciate emerging evidence supporting the use of therapeutic regimens combining targeted agents with PARP inhibitors

### **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

### **FACULTY DISCLOSURES**

Alanna Kaplan, Medical Student – None; Henry S. Park, MD, MPH – RadOncQuestions, LLC, Honorarium-Editor

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.